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1. Introduction 
From studies of rat ventral prostate explants in 
culture, in which testosterone metabolism in the tar- 
get organ can be correlated with testosterone and tes- 
tosterone metabolite activities [ 1,2] , the concept has 
emerged that testosterone may be largely if not exclu- 
sively active through the formation of metabolic de- 
rivative(s) formed in situ. Parallel investigations have 
indicated that an active dihydro-metabolite of testos- 
terone, androstanolone (17&hydroxy-5a-androstan-3- 
one, also known as dihydro-testosterone, DHT) is ac- 
cumulated in bound form in ventral prostate nuclei 
[3-51 whereas a prostatic cytosol receptor binds an- 
drostanolone with a higher affinity than testosterone 
]6,71. 
Whether or not androstanolone formation is an 
obligatory intermediary step in testosterone activity 
in the prostate itself and in other androgen responsive 
structures is still undecided, and therefore a systemat- 
ic measurement of testosterone and androstanolone 
in selected organs of normal adult male rats has been 
undertaken as a first approach for understanding the 
physiological situation. It is believed that the local 
concentration of active steroids might be related to 
the presence and the binding characteristics of high 
affinity receptors possibly involved in hormone action. 
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2. Material and methods 
Normal 3 month old Wistar rats, weighing 250- 
300 g were used throughout the experiments. They 
were killed by decapitation, and plasma and organ 
samples were collected and pooled. 10% Homogen- 
ates of the organs were made by the use of an ultra- 
Turrax, then 4 vol of ethanol containing tracer 
amounts of radioactive testosterone and androstano- 
lone were added. After standing at -20°C overnight, 
the precipitate was eliminated and, after evaporation 
under vacuum, the extracts were taken up in water 
and extracted by ethyl acetate. 
The gas chromatographic electron capture tech- 
nique described by Van der Molen and Groen [8] for 
the measurement of testosterone in human plasma 
was modified in order to allow the measurement of 
testosterone and dihydro-testosterone in rat plasma 
and tissue samples. The ethyl acetate extract was 
dried, redissolved in hexane: benzene (1: 1) and ap 
plied to a silica gel column [9] , followed by a silica 
gel thin-layer chromatography in the benzene:acetone 
(85: 15) system (2 migrations) [2] . Testosterone and 
androstanolone were located using a radiochromato- 
gram scanner, and eluted. Then the heptafluorobutyr- 
ates of testosterone and androstanolone were formed, 
purified by thin-layer chromatography, and measured 
by gas liquid chromatography with electron capture 
detection [lo] . 2Ofl-OH-pregn-4-ene-3-one hepta- 
fluorobutyrate was used as internal standard for tes- 
tosterone heptafluorobutyrate, and testosterone hep- 
tafluorobutyrate was used as internal standard for 
androstanolone heptafluorobutyrate. The limit of 
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Table 1 
Testosterone and androstanolone in rat plasma and tissues’. 
Testosterone Androstanolone 
Plasma 2.5 f o.32 
Seminal vesicles 2.2 f 0.3 
Ventral prostate 2.0 + 0.4 
Levator ani muscle 7.9 f OS4 
Thigh muscles 2.9 * 0.5 
Hypothalamus 13.7 f 2.04 
Pituitary gland 60.5 f 5.54 
Brain parietal cortex 1.3 ?I 0.15 
Kidney 12.5 f 0.54 
Small intestine =z o.24 
’ rig/g (Organs) or ml (plasma). 
: Mean f SEM. 
< o.23 
3.0 f 0.64 
2.8 + OS4 
Q 0.2 
Q 0.4 
2.0 ?r o.44 
<6 
Q 0.4 
3.0 * 1.14 
< 0.2 
G Values too low to be measured accurately. Their upper 
limit is given. 
4 Significantly different from corresponding plasma values 
P G 0.01. 
’ Significantly different from corresponding plasma values 
P < 0.2. 
sensitivity of the method is 0.4 ng of steroid. The 
overall recovery of added tracers is 20-30%. Thus 
the initial 5 g (ml) of tissue (plasma) sample should 
contain at least 2 ng of steroid for processing through 
the entire procedure. All measurements were done in 
triplicate. The coefficient of variation for plasma tes- 
tosterone samples was found to be 10% [lo] . 
3. Results and discussion 
The concentrations of testosterone and dihydrotes- 
tosterone were measured in rat plasma, seminal vesi- 
cles and prostate, Zeuator ani and thigh muscles, hypo- 
thalamus, pituitary gland and brain parietal cortex, 
kidney and small intestine (table 1). 
In the plasma, testosterone is present at a concen- 
tration similar to those previously reported [ 1 l- 131, 
whereas androstanolone is not detected. 
In ventral prostate and seminal vesicles, androstano- 
lone is found at a slightly greater concentration than 
testosterone, which is itself in amount similar to that 
in the plasma. The fact that testosterone concentra- 
tion approaches that of androstanolone is rather unex- 
pected, although testosterone accumulation in pros- 
tate cells might be favored by the relatively high K, 
of testosterone So-reductase [ 141 and the relatively 
high affinity of the cytosol androstanolone receptor 
for testosterone (0.2-0.5 that for androstanolone) 
[7] . In addition, it is not known whether both ster- 
oids are evenly distributed throughout different cell 
types. 
In muscles no androstanolone is found, including 
in the Zevator ani, a classical androgen dependent or- 
gan. Testosterone concentration is higher than in the 
plasma, a finding to be correlated with the presence 
of a cytosol receptor in the levator ani muscle, having 
an affinity for testosterone greater than for andros- 
tanolone [ 151. In skeletal muscles, androgens display 
a well known anabolic action, responsible for the sex- 
ual difference in their development even they are usu- 
ally not considered as typical secondary sex organs. 
The concentration of testosterone in thigh muscles is 
of the order of that found in the plasma, whereas in 
control tissues as intestine or brain cortex the value 
is definitely lower. Therefore it might be possible that 
skeletal muscles contain a testosterone binding pro- 
tein, possibly of feeble abundance and/or difficult to 
solubilize and which may be therefore very difficult 
to demonstrate [ 151 . It is noteworthy that in muscle 
cells which exhibit a purely hypertrophic response to 
testosterone, no androstanolone is found, whereas 
this latter compound has an hyperplastic activity pre- 
viously documented in prostate experiments [ 11. 
In several other organs, kidney, hypothalamus and 
pituitary, there is also testosterone accumulation, 
whereas androstanolone is present in a relatively 
small concentration. As in the muscle, testosterone 
itself may also be implicated in androgen action on 
(mice) kidney [ 161. In the hypothalamus and pitu- 
itary, the nature of the steroid molecule(s) regulating 
the synthesis and secretion of gonadotropin releasing 
hormone(s) and gonadotropins is (are) still controver- 
sial. The present results suggest a role for testosterone 
itself, whereas arguments have been brought recently 
in favor of reduced [ 17-191 or oestrogen [20] me- 
tabolites of testosterone. 
There is possibly some interest that a regulatory 
molecule has to proceed through several transforma- 
tion steps before being active, and the formation of 
different active metabolite(s) in target organs may un- 
dergo a subtle regulation. This mechanism offers the 
possibility of selective pharmacodynamic or therapeu- 
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tic approaches. Testosterone might be a “hormone” 
in the muscles and in some cells of the kidney, the 
hypothalamus and the pituitary, whereas it would be 
a “prehormone” elsewhere, the active molecule being 
androstanolone in the prostate and the seminal vesi- 
cle and possibly also an oestrogen in the hypothala- 
mus. Therefore selective analogues or antagonists 
could be devised in order to act upon the correspond- 
ing target tissues, thus using the metabolism of testos- 
terone as a molecular basis to dissociate its overall ef- 
fects. 
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